Work

Risk-based pricing models and the role they might play in patients’ access to new stem cell therapies

Year: 2024

Type: article

Abstract: Stem cell research is currently undergoing a promising transformation from primarily basic research to increasing emphasis on translation and clinical trials. To reach patients, however, stem cell treatments need to be not only technically but also economically viable. In this commentry we present insights into emerging pricing models that may help ensure access to advanced and expensive treatments like stem cell therapies. Further, we present some reflections on the practical and ethical challenges that these models involve. We provide this information to allow the field of translational stem cell research to think ahead and to raise awareness of the outstanding social and ethical issues.

Source: Regenerative Medicine

DOI: 10.1080/17460751.2024.2441642

Authors: Klaus Hoeyer, Anne Sofie Borsch, Kim Bak Jensen, Agnete Kirkeby, Casper Steenholdt, Sarah Wadmann

Institutions: University of Copenhagen, Novo Nordisk Foundation Center for Stem Cell Medicine, Herlev Hospital, VIVE - The Danish Center for Social Science Research

Language: English

Topic: Biomedical Ethics and Regulation

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green